US FDA declines to approve Cingulate's ADHD drug
02/06/2026 13:05
US FDA declines to approve Cingulate's ADHD drug June 2 (Reuters) - Cingulate CING.O said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
(Reporting by Kunal Das and Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)